Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel
NASDAQ:DBVT

DBV Technologies 2/14/2026 Earnings Report

DBV Technologies logo
$19.73 -0.26 (-1.30%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

DBV Technologies EPS Results

Actual EPS
-$1.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$0.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Date
2/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

DBV Technologies Earnings Headlines

HC Wainwright Brokers Decrease Earnings Estimates for DBVT
May 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30756696
Citizens Jmp Forecasts Strong Price Appreciation for DBV Technologies (NASDAQ:DBVT) Stock
May 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30754848
The AI stocks about to become worthless (and one that isn't)
Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being built at a classified government facility in Tennessee could make today's leading AI models obsolete overnight. He compares it to the iPhone moment that wiped out Nokia, BlackBerry, and Motorola. When this machine comes online, it will reportedly accelerate AI breakthroughs 360-fold - compressing five years of progress into five days. Navellier has identified specific stocks he'd sell before this hits, and one ticker he'd buy before May 5th.tc pixel
May 8 at 1:00 AM  |  InvestorPlace (Ad)
DBV Technologies Reports First Quarter 2026 Financial Results
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285516/0/en/dbv-technologies-reports-first-quarter-2026-financial-results.html
DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue
April 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891707-dbv-technologies-a-cohort-driven-model-that-could-support-blockbuster-viaskin-revenue
DBV Technologies SA - Depositary Receipt (DBVT) price target increased by 32.54% to 31.33
April 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/dbv-technologies-sa-depositary-receipt-dbvt-price-target-increased-by-32-54-to-31-33/ar-AA211m5i
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT) SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy.

Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge.

Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases.

View DBV Technologies Profile
Earnings Tools